Midlife cardiovascular risk impacts executive function: Framingham offspring study

Alzheimer Disease and Associated Disorders

Volumn 28, Issue 1, 2014, Pages 16-22

  Nishtala, Arvind ^a   Preis, Sarah R ^b   Beiser, Alexa ^a,b   Devine, Sherral ^a   Hankee, Lisa ^a   Seshadri, Sudha ^a   Wolf, Philip A ^a   Au, Rhoda ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

apolipoproteinE allele 4; executive function; mild cognitive impairment; neuropsychological assessment

Indexed keywords

CARDIOVASCULAR DISEASES; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RISK FACTORS;

EID: 84894419842     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3182a715bc     Document Type: Article

References (40)

1. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001;322:1447-1451.
2. Schnaider Beeri M, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology. 2004;63:1902-1907.
3. Tyas SL, White LR, Petrovitch H, et al. Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. Neurobiol Aging. 2003;24:589-596.
4. Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277-281.
5. Luchsinger JA, Reitz C, Honig LS, et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65:545-551.
6. Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011;77:461-468.
7. Arntzen KA, Schirmer H, Wilsgaard T, et al. Impact of cardiovascular risk factors on cognitive function: the Tromso study. Eur J Neurol. 2011;18:737-743.
8. Knopman D, Boland LL, Mosley T, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56:42-48.
9. Unverzagt FW, McClure LA, Wadley VG, et al. Vascular risk factors and cognitive impairment in a stroke-free cohort. Neurology. 2011;77:1729-1736.
10. Galanis DJ, Petrovitch H, Launer LJ, et al. Smoking history in middle age and subsequent cognitive performance in elderly Japanese-American men. The Honolulu-Asia Aging Study. Am J Epidemiol. 1997;145:507-515.
11. Kilander L, Nyman H, Boberg M, et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998;31:780-786.
12. Kilander L, Nyman H, Boberg M, et al. The association between low diastolic blood pressure in middle age and cognitive function in old age. A population-based study. Age Ageing. 2000;29:243-248.
13. Kivipelto M, Helkala EL, Hanninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology. 2001;56:1683-1689.
14. Launer LJ, Masaki K, Petrovitch H, et al. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274: 1846-1851.
15. Swan GE, Carmelli D, Larue A. Systolic blood pressure tracking over 25 to 30 years and cognitive performance in older adults. Stroke. 1998;29:2334-2340.
16. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287: 356-359.
17. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279.
18. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-292.
19. Caselli RJ, Reiman EM, Locke DE, et al. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol. 2007;64:1306-1311.
20. Knopman DS, Mosley TH, Catellier DJ, et al. Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimers Dement. 2009;5:207-214.
21. Whitehair DC, Sherzai A, Emond J, et al. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement. 2010;6:412-419.
22. Blair CK, Folsom AR, Knopman DS, et al. Midlife cardiovascular risk factors, APOE genotype and cognitive decline in a middle-aged cohort. Neurology. 2005;64:268-276.
23. Carmelli D, Swan GE, Reed T, et al. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology. 1998;50:1580-1585.
24. Haan MN, Shemanski L, Jagust WJ, et al. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA. 1999;282:40-46.
25. Peila R, White LR, Petrovich H, et al. Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study. Stroke. 2001;32: 2882-2889.
26. Zade D, Beiser A, McGlinchey R, et al. Interactive effects of apolipoprotein E type 4 genotype and cerebrovascular risk on neuropsychological performance and structural brain changes. J Stroke Cerebrovasc Dis. 2010;19:261-268.
27. Qiu C, Winblad B, Fratiglioni L. Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population. Neurol Res. 2006;28:650-656.
28. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-318.
29. Feinleib M, Kannel WB, Garrison RJ, et al. The Framingham Offspring Study. Design and preliminary data. Prev Med. 1975;4:518-525.
30. D'Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994;25:40-43.
31. Llewellyn DJ, Lang IA, Xie J, et al. Framingham Stroke Risk Profile and poor cognitive function: a population-based study. BMC Neurol. 2008;8:12.
32. Truelsen T, Lindenstrom E, Boysen G. Comparison of probability of stroke between the Copenhagen City Heart Study and the Framingham Study. Stroke. 1994;25:802-807.
33. Au R, Seshadri S, Wolf PA, et al. New norms for a new generation: cognitive performance in the framingham offspring cohort. Exp Aging Res. 2004;30:333-358.
34. Kaplan E FD, Morris RG, Delis DC. The Weschler Adult Intelligence Scale - Revised as a Neuropsychological Instrument. San Antonio, TX: Psychological Corporation; 1991.
35. Libon DJ, Bondi MW, Price CC, et al. Verbal serial list learning in mild cognitive impairment: a profile analysis of interference, forgetting, and errors. J Int Neuropsychol Soc. 2011;17:905-914.
36. Bettcher BM, Giovannetti T, Macmullen L, et al. Error detection and correction patterns in dementia: a breakdown of error monitoring processes and their neuropsychological correlates. J Int Neuropsychol Soc. 2008;14:199-208.
37. Hankee LDPS, Beiser AS, Devine SA, et al. Qualitative neuropsychological measures: normative data on executive functioning tests from the Framingham Offspring Study. Exp Aging Res. 2013. [Epub ahead of print].
38. Luchsinger JA, Reitz C, Patel B, et al. Relation of diabetes to mild cognitive impairment. Arch Neurol. 2007;64: 570-575.
39. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA. 2006;103:5644-5651.
40. Wisniewski T, Castano EM, Golabek A, et al. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030-1035.